Biopharma & Life Sciences

Avantor Executive Compensation (FY25)

Name: Avantor (AVTR) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

AVTR · Radnor, PA · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Emmanuel Ligner

Median of the other named officers

$5,987,816

5 officers, excluding the chief executive

Latest say-on-pay support

May 7, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on Avantor

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

Data as of October 18, 2026Latest filing (8-K): May 12, 2026

10 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Avantor brief$1,500Get the executive brief

Velarion Member, one year

406 figures on this page: 400 cited to the filing that reported them, 6 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is Avantor's chief executive and what were they paid?

Emmanuel Ligner was paid $5,895,624 in total compensation as Director, President and Chief Executive Officer for fiscal 2025.

What was Avantor's say-on-pay result?

Shareholders supported the say-on-pay proposal with 96.9% of votes cast including abstentions in favor at the meeting held May 7, 2026 for fiscal 2025.

Which companies are in Avantor's peer group?

The disclosed peer group names Agilent Technologies, Inc., Baxter International, Inc., Bio-Rad Laboratories, Inc., Biogen Inc. and Bruker Corporation, among others.

What is Avantor's chief executive pay ratio?

The disclosed chief executive pay ratio for fiscal 2025 is 148:1, against median employee compensation of $47,791.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Michael Stubblefield President and Chief Executive Officer	◇	—	◇	◇	—	—	◇	◇
Thomas Szlosek Former Executive Vice President and Chief Financial Officer	◇	—	◇	◇	—	◇	◇	◇
Frederic Vanderhaegen Executive Vice President Europe	◇	—	◇	◇	—	—	◇	◇
Gerard Brophy Former Executive Vice President, Biopharma Production	◇	—	◇	◇	—	◇	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Michael Stubblefield President and Chief Executive Officer	◇	—	◇	◇	◇	◇	◇	◇
R. Brent Jones Executive Vice President and Chief Financial Officer	◇	◇	◇	◇	◇	—	◇	◇
Randy Stone Executive Vice President	◇	—	◇	◇	◇	—	◇	◇
Frederic Vanderhaegen Executive Vice President Europe	◇	—	◇	◇	◇	—	◇	◇
Gerard Brophy Former Executive Vice President, Biopharma Production Departed during or after this year	◇	—	◇	◇	◇	◇	◇	◇
Thomas Szlosek Former Executive Vice President and Chief Financial Officer Departed during or after this year	◇	—	◇	◇	—	◇	◇	◇
James Bramwell Executive Vice President and Chief Commercial Officer	◇	—	◇	◇	◇	◇	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Michael Stubblefield President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
R. Brent Jones Executive Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Benoit Gourdier Executive Vice President and Chief Operating Officer	◇	—	◇	◇	◇	—	◇	◇
Randy Stone Former Executive Vice President, Laboratory Solutions Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
James Bramwell Executive Vice President and Chief Commercial Officer	◇	—	◇	◇	◇	—	◇	◇
Claudius Sokenu Executive Vice President, General Counsel and Corporate Secretary	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Michael Stubblefield Former Chief Executive Officer Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
R. Brent Jones Executive Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Corey Walker President Laboratory Solutions	◇	—	◇	◇	◇	—	◇	◇
Emmanuel Ligner Director, President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Benoit Gourdier Executive Vice President Bioscience Production	◇	—	◇	◇	◇	—	◇	◇
Claudius Sokenu Executive Vice President, Chief Legal and Compliance Officer	◇	—	◇	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Benoit Gourdier	RSU	◇	—	—	◇	—	—	◇
Benoit Gourdier	OPTION	◇	—	—	◇	—	◇	◇
Benoit Gourdier	PSU	◇	◇	◇	—	◇	—	◇
Benoit Gourdier	RSU	◇	—	—	◇	—	—	◇
Claudius Sokenu	RSU	◇	—	—	◇	—	—	◇
Claudius Sokenu	PSU	◇	◇	◇	—	◇	—	◇
Claudius Sokenu	RSU	◇	—	—	◇	—	—	◇
Claudius Sokenu	OPTION	◇	—	—	◇	—	◇	◇
Corey Walker	PSU	◇	◇	◇	—	◇	—	◇
Corey Walker	RSU	◇	—	—	◇	—	—	◇
Corey Walker	OPTION	◇	—	—	◇	—	◇	◇
Corey Walker	RSU	◇	—	—	◇	—	—	◇
Emmanuel Ligner	OPTION	◇	—	—	◇	—	◇	◇
Emmanuel Ligner	RSU	◇	—	—	◇	—	—	◇
Michael Stubblefield	RSU	◇	—	—	◇	—	—	◇
Michael Stubblefield	PSU	◇	◇	◇	—	◇	—	◇
Michael Stubblefield	OPTION	◇	—	—	◇	—	◇	◇
R. Brent Jones	RSU	◇	—	—	◇	—	—	◇
R. Brent Jones	OPTION	◇	—	—	◇	—	◇	◇
R. Brent Jones	PSU	◇	◇	◇	—	◇	—	◇
R. Brent Jones	RSU	◇	—	—	◇	—	—	◇

Fiscal 2023, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Emmanuel Ligner	Option	◇	—	◇	18/08/2035
	PSU	◇	◇	—	—
Claudius Sokenu	Option	◇	—	◇	02/20/35
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	02/23/34
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	07/24/33
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
Corey Walker	Option	◇	—	◇	02/20/35
	Option	◇	—	◇	06/21/34
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
R. Jones	Option	◇	—	◇	08/07/33
	Option	◇	—	◇	02/23/34
	Option	◇	—	◇	02/20/35
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
Benoit Gourdier	Option	◇	—	◇	10/02/33
	Option	◇	—	◇	02/23/34
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	02/20/35
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
Michael Stubblefield	Option	◇	—	◇	09/30/26
	Option	◇	—	◇	12/13/27
	Option	◇	—	◇	02/23/32
	Option	◇	—	◇	02/20/35
	PSU	◇	◇	—	—
	Option	◇	—	◇	02/25/31
	PSU	◇	◇	—	—
	Option	◇	—	◇	02/24/33
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	02/20/30
	Option	◇	—	◇	02/23/34

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Benoit Gourdier

Executive Vice President Bioscience Production · Employment agreement · dated July 19, 2023

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇
Clawback	◇

Claudius Sokenu

Executive Vice President, Chief Legal and Compliance Officer · citing a 2026 filing

Change-in-control trigger

◇

Corey Walker

President Laboratory Solutions · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Emmanuel Ligner

Director, President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jonathan Peacock Board chair	◇	◇	—	—	—	—	◇
Dame Louise Makin	◇	◇	—	—	—	◇	◇
Joseph Massaro	◇	◇	—	—	—	—	◇
Gregory Summe	◇	◇	—	—	—	—	◇
Michael Severino	◇	◇	—	—	—	—	◇
Mala Murthy	◇	◇	—	—	—	—	◇
Juan Andres	◇	◇	—	—	—	—	◇
Lan Kang	◇	◇	—	—	—	—	◇
John Carethers	◇	◇	—	—	—	—	◇
Gregory T. Lucier	◇	◇	—	—	—	—	◇
Sanjeev Mehra	◇	◇	—	—	—	—	◇

Simon Dingemans and Emmanuel Ligner served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee member	◇
Compensation committee member	◇
Nominating and governance member	◇

Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Agilent Technologies, Inc. A
Baxter International, Inc. BAX
Bio-Rad Laboratories, Inc. BIO
Biogen Inc. BIIB
Bruker Corporation BRKR
Charles River Laboratories International, Inc. CRL
Edwards Lifesciences EW
Hologic, Inc. HOLX
Illumina, Inc. ILMN
IQVIA Holdings Inc. IQV
Laboratory Corp. of America symbol not shown
Mettler-Toledo International Inc MTD
Quest Diagnostics Inc. DGX
Revvity, Inc. RVTY
Waters Corporation WAT
Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	May 7, 2026	=	◇	◇	◇
2024	May 8, 2025	=	◇	◇	◇
2023	May 9, 2024	=	◇	◇	◇
2022	May 11, 2023	=	◇	◇	◇
2021	May 12, 2022	=	◇	◇	◇
2019	May 7, 2020	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Emmanuel Ligner (Director, President and Chief Executive Officer), FY2025 total compensation $5,895,624 (base salary $379,297) [exec_comp, SEC accession 0001628280-26-021572, filed 2026-03-27]

What this page does not include

Everything above is a fact Avantor disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Avantor sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

406 figures on this page: 400 cited to the filing that reported them, 6 calculated from figures it prints.

400 cited to the filing

6 calculated from the filing

Documents cited

8-K, filed May 12, 2026
0001628280-26-034146
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed March 27, 2026
0001628280-26-021572
CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Director Fees · and 4 more sections
EX-10, filed February 11, 2026
0001628280-26-007118
EX-10.37
8-K, filed May 12, 2025
0001722482-25-000143
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed March 28, 2025
0000950170-25-046778
Summary Compensation Table
8-K, filed May 10, 2024
0001722482-24-000109
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed March 29, 2024
0001193125-24-082080
Executive Compensation Tables
8-K, filed May 11, 2023
0001722482-23-000103
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 13, 2022
0001722482-22-000121
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 8, 2020
0001722482-20-000096

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Avantor executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AVTR (accessed 2026).

Short form: data: Velarion

The paid brief for Avantor

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

10 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/AVTR/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Avantor executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Avantor and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers Avantor discloses

The companies named in AVTR's own disclosed peer group.

Agilent Technologies, Inc.Baxter International, Inc.Bio-Rad Laboratories, Inc.Biogen Inc.Bruker Corporation Charles River Laboratories International, Inc.Edwards Lifesciences Hologic, Inc.Illumina, Inc.IQVIA Holdings Inc.Mettler-Toledo International Inc Quest Diagnostics Inc.Revvity, Inc.Waters Corporation Zimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Avantor

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for Avantor

Biopharma & Life Sciences rankings

Peers Avantor discloses

Terms on this page